Results 61 to 70 of about 3,996,783 (390)
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun+8 more
wiley +1 more source
Immune checkpoint inhibitors (ICI) represent new anticancer agents and have been used worldwide. However, ICI can potentially induce life-threatening severe cutaneous adverse reaction (SCAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis ...
Chun-Bing Chen+31 more
doaj +1 more source
Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health Administration
Objective Though used frequently to treat flare, risk of chronic opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed chronic opioids over time.
Lindsay N. Helget+7 more
wiley +1 more source
The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model [PDF]
Introduction: Ferric carboxymaltose is a next-generation polynuclear iron(III)-hydroxide carbohydrate complex for intravenous iron therapy belonging to the class of so-called non-biological complex drugs.
Angerosa, Margarita+2 more
core +1 more source
Pharmacogenetics of hypersensitivity drug reactions [PDF]
Adverse drug reactions are a significant cause of morbidity and mortality and represent a major burden on the healthcare system. Some of those reactions are immunologically mediated (hypersensitivity reactions) and can be clinically subdivided into two categories: immediate reactions (IgE-related) and delayed reactions (T-cell-mediated).
NEGRINI, SIMONE, Becquemont, Laurent
openaire +5 more sources
Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao+8 more
wiley +1 more source
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens
Recently, increasing data show that immunotherapy could be a powerful weapon against cancers. Comparing to the traditional surgery, chemotherapy or radiotherapy, immunotherapy more specifically targets cancer cells, giving rise to the opportunities to ...
Ren-You Pan+6 more
doaj +1 more source
Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug
Background: The World Health Organization Global Tuberculosis Report 2021 defines tuberculosis as the second infectious disease that causes sickness and death after COVID 19 and ranks it as the 13th among the global causes of death.
Zeynep Yegin Katran+3 more
doaj +1 more source
Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq+4 more
wiley +1 more source
Safety Evaluation of Repeated Application of Polymeric Microarray Patches in Miniature Pigs
This study demonstrates the safety of repeated application of three types of microarray patches (MAPs), hydrogelforming, dissolving, and implantable, over four weeks in miniature pigs. No adverse skin or systemic effects were observed, supporting the clinical potential of MAPs as safe and effective drug delivery platforms.
Qonita Kurnia Anjani+4 more
wiley +1 more source